BeOne Medicines (BEIGF) Non-Current Deffered Revenue (2017 - 2023)

BeOne Medicines (BEIGF) has 6 years of Non-Current Deffered Revenue data on file, last reported at $300000.0 in Q4 2023.

• Non-Current Deffered Revenue for Q4 2023 came in at $300000.0, down 99.29% year-over-year; the trailing twelve-month figure through Dec 2023 was $300000.0 (down 99.29% YoY), and the FY2023 annual result was $300000.0, down 99.29% from the prior year.
• Non-Current Deffered Revenue was little changed at $300000.0 in Q4 2023 per BEIGF's latest filing, from $300000.0 in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $220.3 million in Q4 2021 and troughed at $300000.0 in Q3 2023.
• A 4-year average of $81.6 million and a median of $52.3 million in 2021 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2022 and 2023: Non-Current Deffered Revenue soared 186.77% in 2022, then sank 99.8% in 2023.
• A 4-year view of Non-Current Deffered Revenue shows it stood at $8.2 million in 2019, then soared by 2573.41% to $220.3 million in 2021, then sank by 80.92% to $42.0 million in 2022, then plunged by 99.29% to $300000.0 in 2023.
• Business Quant data shows BEIGF's Non-Current Deffered Revenue at $300000.0 in Q4 2023, $300000.0 in Q3 2023, and $24.3 million in Q2 2023.